Clinical Trials

Gastrointestinal Tumors

Recruitment stopped
Ongoing Recruitment

Pancreatic Carcinoma

ESPAC-5F

(neoadjuvant)
Title:EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 5: Four arm, prospective, multicentre, randomised, feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy
Indication:Pancreatic Adenocarcinoma
Type of study:Phase II
Contact: Birgit Erni (Study Nurse)
[birgit.erni@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Thilo Hackert (Leiter klinische Prüfung)
Trial Register: Die Studie ist beim "ISRCTN - International Standard Randomised Controlled Trial Number Register" (Controlled-Trials.com) registriert. Siehe ISRCTN89500674 / NCT-2014-1230
EudraCT: 2013-003932-56 (siehe EU klinisches Studienregister)

HALO-109-301

(first-line)
Title:A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Indication:Adenocarcinoma
Type of study:Phase III
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02715804
EudraCT: 2015-004068-13 (siehe EU klinisches Studienregister)

Clarinet forte (8-79-52030-326)

(second-line)
Title:Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days
Indication:Apudoma Carcinoid Tumor Neoplasms Neuroendocrine Tumors Pancreatic Neoplasms
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02651987
EudraCT: 2014-005607-24 (siehe EU klinisches Studienregister)

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:DNA Repair-Deficiency Disorders
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

BMS-CA202-103

Title:A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Indication:Colorectal Neoplasms, Pancreatic Neoplasms
Type of study:Phase I/II
Contact: Sebastian Schülke (Kontaktperson)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: PD Dr. med. Jürgen Krauss (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03184870
EudraCT: 2017-001725-40 (siehe EU klinisches Studienregister)

Heparflow

Title:Intraoperative Evaluation of the Hepatic Artery Blood Flow during Pancreatoduodenectomy
Indication:Patienten bei denen eine partielle oder totale Pankreatoduodenectomie durchgeführt wird
Type of study:Phase N/A
Contact: Leonie Frank-Moldzio (Kontaktperson)
[Leonie.Frank-Moldzio@med.uni-heidelberg.de]
Investigator: Prof. Dr. Oliver Strobel (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

META-PAC

Title:Prospektive Studie zum Plasma-Metabolom Multimarker Panel MxP®PancreasScore zum Ausschluss eines Pankreaskarzinoms in Risikokohorten
Indication:Pankreaskarzinoms
Type of study:Phase N/A
Contact: Birgit Erni (Kontaktperson)
[birgit.erni@med.uni-heidelberg.de]
Investigator: Prof. Dr. Oliver Strobel (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PANDRA II

Title:Vergleich zwischen abdomineller Drainageneinlage mit keiner Drainageneinlage nach offener oder laparoskopischer Pankreaslinksresektion
Indication:Patienten mit malignen und benignen Erkrankungen des Pankreaskorpus oder Pankreasschwanzes, die für eine Pankreaslinksresektion geplant sind
Type of study:Phase N/A
Contact: Birgit Erni (Study Nurse)
[birgit.erni@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Thilo Hackert (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PancER

Title:Conventional partial pancreatoduodenectomy versus an uncinate first, extended partial pancreatoduodenectomy approach for the resection of pancreatic head ductal adenocarcinoma (PancER)
Indication:Suspected pancreatic ductal adenocarcinoma of the pancreatic head
Type of study:Phase N/A
Contact: Birgit Erni (Study Nurse)
[birgit.erni@med.uni-heidelberg.de]
Investigator: PD Dr. med André Mihalejevic (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

STARTRK-2/ RXDX-101-92

Title:AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Indication:Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003385-84 (siehe EU klinisches Studienregister)

Gastric and Oesophageal Carcinomas

MATEO (AIO-YMO-0111)

(first-line)
Title:Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
Indication:Metastatic Esophagogastric Cancer (Adenocarcinoma)
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Martin Haag (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02128243
EudraCT: 2013-002742-37 (siehe EU klinisches Studienregister)

Renaissance (FLOT5)

(first-line)
Title:Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI)
Indication:Adenocarcinoma Stomach Neoplasms
Type of study:Phase III
Contact: Lisa Michel (Study Nurse)
[Lisa.Michel@med.uni-heidelberg.de]
Investigator: Dr. med. Martin Haag (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02578368
EudraCT: 2014-002665-30 (siehe EU klinisches Studienregister)

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:DNA Repair-Deficiency Disorders
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

OPPOSITE

(Biomarker)
Title:Molecular Outcome Prediction of Neoadjuvant Systemic Treatment in Esophagogastric Carcinoma
Indication:Bösartige Neubildung des Ösophagus, Bösartige Neubildung des Magens
Type of study:Phase N/A
Contact: Dr. med. Martin Haag (Kontaktperson)
[GeorgMartin.Haag@med.uni-heidelberg.de]
Investigator: Dr. med. Martin Haag (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03429816
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

BioNTech –Forschungsstudie (RB_T002)

(diagnostisch, Früherkennung, Screening)
Title:Identifikation von individuellen Krebsmutationen und Testung ihrer Immunogenität
Indication:-
Type of study:Phase N/A
Contact: Sebastian Schülke (Study Nurse)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Dirk Jäger (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

FRACTION/CA018-003

Title:A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer
Indication:Advanced Gastric Cancer
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Martin Haag (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02935634
EudraCT: 2016-002807-24 (siehe EU klinisches Studienregister)

Colorectal Carcinaomas (CRC)

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:DNA Repair-Deficiency Disorders
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

PICCASSO

(second-line, metastasiert, therapeutisch)
Title:A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Indication:Colorectal Neoplasms
Type of study:Phase I
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Martin Haag (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03274804
EudraCT: 2017-000193-11 (siehe EU klinisches Studienregister)

ColoCare Studie

(Biomarker, epidemiologisch, Prävention, diagnostisch)
Title:“Transdisciplinary Research in Colon Cancer Prognosis.” Prospektive Kohortenstudie
Indication:Kolorektales Karzinom, Stadium I - IV
Type of study:Phase N/A
Contact: Birgit Erni (Kontaktperson)
[birgit.erni@med.uni-heidelberg.de]
Investigator: Prof. Dr. Alexis Ulrich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02391597
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

BioNTech –Forschungsstudie (RB_T002)

(diagnostisch, Früherkennung, Screening)
Title:Identifikation von individuellen Krebsmutationen und Testung ihrer Immunogenität
Indication:-
Type of study:Phase N/A
Contact: Sebastian Schülke (Study Nurse)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Dirk Jäger (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

DACHS

(epidemiologisch, Prävention)
Title:DACHS: Chancen der Verhütung durch Screening (potentials of prevention through screening)
Indication:GIT
Type of study:Phase N/A
Contact: Dr. Michael Hoffmeister (Kontaktperson)
[m.hoffmeister@dkfz-heidelberg.de]
Investigator: Dr. Michael Hoffmeister (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Blitz-Studie

(Prävention, diagnostisch, Früherkennung, Screening)
Title:Begleitende Evaluierung innovativer Testverfahren zur Darmkrebs-Früherkennung
Indication:colorectal cancer
Type of study:Phase N/A
Contact: Jason Hochhaus (Kontaktperson)
[j.hochhaus@dkfz-heidelberg.de]
Investigator: Prof. Dr. Hermann Brenner (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

BMS-CA202-103

Title:A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Indication:Colorectal Neoplasms, Pancreatic Neoplasms
Type of study:Phase I/II
Contact: Sebastian Schülke (Kontaktperson)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: PD Dr. med. Jürgen Krauss (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03184870
EudraCT: 2017-001725-40 (siehe EU klinisches Studienregister)

GHOST

Title:Ghost-ileostomy versus conventional loop ileostomy in patients undergoing low anterior resection for rectal cancer
Indication:Patients undergoing elective low anterior resection for rectal cancer
Type of study:Phase N/A
Contact: Birgit Erni (Study Nurse)
[birgit.erni@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Markus Diener (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

ReLap Study

Title:Relaparotomie Studie - Prospektive Studie zum Versorgungsstandard und Outcome von relaparotomierten Patienten mit einem randomisierten Schritt (Faszienverschluss)
Indication:Abdominelle Re-Operationen Primäre Laparotomie
Type of study:Phase N/A
Investigator: Pascal Probst (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

STARTRK-2/ RXDX-101-92

Title:AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Indication:Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003385-84 (siehe EU klinisches Studienregister)

Vaccibody (VBN-01)

Title:An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockade
Indication:Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN
Type of study:Phase I
Contact: Sebastian Schülke (Kontaktperson)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: PD Dr. med. Jürgen Krauss (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2017-002474-39 (siehe EU klinisches Studienregister)

Cholecystic and Gall Bladder Carcinomas

ACTICCA-1

(adjuvant)
Title:Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Indication:Cholangio carcinoma; Gallbladder Neoplasms
Type of study:Phase III
Contact: Margit Peters-Hornig (Study Nurse)
[margit.peters-hornig@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02170090
EudraCT: 2012-005078-70 (siehe EU klinisches Studienregister)

HEP-0117/IMMUCHEC

Title:A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)
Indication:CarcinomaCholangiocarcinomaUrinary Bladder NeoplasmsGallbladder Neoplasms
Type of study:Phase II
Contact: Margit Peters-Hornig (Study Nurse)
[margit.peters-hornig@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03473574
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

IMMUCHEC/AIO-HEP-0117

Title:A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladder carcinoma (IMMUCHEC)
Indication:Gall Bladder Carcinoma
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03473574
EudraCT: 2017-001538-25 (siehe EU klinisches Studienregister)

Hepatocellular Carcinomas

HIMALAYA

(first-line)
Title:A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Indication:CarcinomaCarcinoma, Hepatocellular
Type of study:Phase III
Investigator: Margit Peters-Hornig (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03298451
EudraCT: 2016-005126-11 (siehe EU klinisches Studienregister)

CBGJ398X2204

(second-line)
Title:A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Indication:Cholangiocarcinoma
Type of study:Phase II
Contact: Ulrike Lauterbach (Study Nurse)
[Ulrike.Lauterbach@med.uni-heidelberg.de]
Investigator: PD Dr. med. Karl-Heinz Weiss (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02150967
EudraCT: 2013-005085-19 (siehe EU klinisches Studienregister)

PriMalStHep

(chirurgisch)
Title:Randomisiert kontrollierte Studie zur Verwendung des Pringle Maneuvers zur Verringerung des Blutverlustes während der Stapler Leberresektion
Indication:Patienten mit Indikation zu Hemihepatektomie
Type of study:Phase N/A
Contact: Dagmar Anders (Kontaktperson)
[Dagmar.Anders@med.uni-heidelberg.de]
Investigator: Dr. med. Philipp Houben (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

RELY

(chirurgisch)
Title:Resection of colorectal liver metastases with or without routine hilar lymphadenectomy
Indication:Colorectal NeoplasmsNeoplasm MetastasisLiver Neoplasms
Type of study:Phase N/A
Contact: Dagmar Anders (Kontaktperson)
[Dagmar.Anders@med.uni-heidelberg.de]
Investigator: Prof. Dr. Alexis Ulrich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01073358
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PROMETHEUS-01

(Schwerionentherapie, radiologisch)
Title:Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with Carbon Ion Radiotherapy
Indication:Hepatozelluläres Karzinom
Type of study:Phase I
Contact: Dr. med. Stefan Körber (Kontaktperson)
[Stefan.Koerber@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Jürgen Debus (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01167374
EudraCT: 2010-018328-23 (siehe EU klinisches Studienregister)

CIN Novartis

Title:A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
Indication:CarcinomaCarcinoma, Hepatocellular
Type of study:Phase I/II
Contact: Nadine Heydrich (Study Nurse)
[Nadine.Heydrich@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02795429
EudraCT: 2015-005417-76 (siehe EU klinisches Studienregister)

PHOCUS

Title:A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Indication:CarcinomaCarcinoma, Hepatocellular Vaccinia
Type of study:Phase III
Contact: Stefanie Hofmann (Kontaktperson)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02562755
EudraCT: 2014-001985-86 (siehe EU klinisches Studienregister)